NCT06641414: An ongoing trial by Ascentage Pharma Group Inc.
This trial is ongoing. It must report results 4 years, 6 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06641414 |
|---|---|
| Title | A Global Multicenter, Double-blind, Randomized, Registrational Phase 3 Study of Lisaftoclax (APG-2575) in Combination With Azacitidine (AZA) in Patients With Newly Diagnosed Higher Risk Myelodysplastic Syndrome (HR-MDS) (GLORA-4). |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Jan. 22, 2025 |
| Completion date | June 30, 2029 |
| Required reporting date | June 30, 2030, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | None |